Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

3.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group..

Ann Neurol. 2002 May;51(5):604-12.

PMID:
12112107
4.
7.
9.
10.
11.

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, et al.

Neurology. 1994 Sep;44(9):1756-9.

PMID:
7936311
12.

The effect of deprenyl and levodopa on the progression of Parkinson's disease.

Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, Bushenbark K, Lilienfeld D, Esterlitz J.

Ann Neurol. 1995 Nov;38(5):771-7.

PMID:
7486869
13.

Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.

Pålhagen S, Heinonen EH, Hägglund J, Kaugesaar T, Kontants H, Mäki-Ikola O, Palm R, Turunen J.

Neurology. 1998 Aug;51(2):520-5.

PMID:
9710028
14.
15.

A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts.

Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I; Parkinson Study Group DATATOP and PRECEPT investigators..

Mov Disord. 2009 Dec 15;24(16):2370-8. doi: 10.1002/mds.22828.

PMID:
19908310
16.
17.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group..

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
18.

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Tetrud JW, Langston JW.

Science. 1989 Aug 4;245(4917):519-22.

PMID:
2502843
20.

Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.

Myllylä VV, Sotaniemi KA, Hakulinen P, Mäki-Ikola O, Heinonen EH.

Acta Neurol Scand. 1997 Apr;95(4):211-8.

PMID:
9150811
Items per page

Supplemental Content

Support Center